Our Proprietary Technology
Is a one-of-a-kind nanocatalyst that promotes healing and protect wounds from infection. It is biocompatible and selectively targets pathogens (virus, bacteria and fungi).
The nanoparticle catalytic efficiency in wound healing was evaluated in a diabetic animal model. The use of the nanoparticle enhanced the natural healing processes with a faster remodeling stage in the study. The biological effects of the nanoparticle were:
NanoSALV was used to treat a diabetic foot ulcer in a 58-year old male patient. The patient presented type 2 diabetes mellitus with 13 years of evolution. This patient was already scheduled for amputation. In order to avoid the amputation, the patient was included into the clinical trial and treated with NanoSALV. In this case, NanoSALV was successful at treating the diabetic foot ulcer to avoid the already prescribed amputation. After a month of treatment, the necrotic tissue of the toes disappeared presenting complete epithelialization below them. After two months of treatment, the injury in the base of the heel was completely clean and had a multiplying granulating tissue. In conclusion, NanoSALV was successful in treating the patient’s diabetic foot ulcer.
NanoSALV was used to treat a diabetic foot ulcer in a 62-year old female with several comorbidities and chonich complications of diabetes. The diabetic foot ulcer was debrided prior to NanoSALV administration. NanoSALV was applied over the ulcer every second day for 10 months. Significant improvement was observed in the wound healing process since the first applications. The infection was limited, and tissue regeneration was enhanced until complete healing of the ulcer. After 10 months, the scar was all re-modeled, without any inflammatory signs and with health skin
During our clinical study, NanoSALV was used to treat patients with severe diabetic foot ulcers. In this study, some patients' wounds were infected, had blood flow less than 10%, had exposed bone and tendon, and had surface areas up to 70 cm2. NanoSALV was applied every 48 hours during the treatment. Initially 62 patients were studied: 47 males and 15 females, with a minimum age of 21 years and a maximum of 83 years, wound evolution time was from 1 month to 2 years. Of the 55 patients who completed the required visitations for the study, NanoSALV eliminated all pathogens identified in the wounds and achieved 100% wound closure; avoiding amputation in all cases.
Conducted under ISO10993 standards
Conducted under the AOAC standard, Eliminated Gram(+) & Gram(-) bacteria, and fungi
Eliminated H1N1, Rotavirus, and SARS-CoV-2
NanoTess is a social enterprise commercializing health and decontamination products. Our company is governed by our social mandate to ensure accessibility for all.
Copyright © 2020 NanoTess - All Rights Reserved.